Bristol-Myers slips as Citi says Pfizer not interested in acquisition

Shares of Bristol-Myers Squibb are slipping after Citi analyst Andrew Baum said Pfizer's CEO made it clear to him that the latter has no interest in acquiring the company in the absence of transformational data or a de-rating in the stock.